|
|
|
| Clinical effect of Jinghua Weikang Capsules combined with quadruple therapy in the treatment of Helicobacter pylori positive senile chronic gastritis |
| JIANG Xin LIU Dan▲ HAN Lin CHENG Li |
| Department of Gastroenterology, Dandong Central Hospital, Liaoning Province, Dandong 118002, China |
|
|
|
Abstract Objective To explore clinical efficacy of Jinghua Weikang Capsules combined with quadruple therapy in the treatment of Helicobacter pylori (Hp) positive elderly chronic gastritis. Methods One hundred and twelve Hp positive elderly patients with chronic gastritis admitted to Dandong Central Hospital from March 2015 to September 2018 were selected and divided into control group and study group according to the random number table method, with 56 cases in each group. Control group was given quadruple therapy, and study group was treated with Jinghua Weikang Capsules on the basis of control group. Clinical efficacy, traditional Chinese medicine symptom score, inflammatory factors, Hp eradication rate and adverse reactions of two groups were compared. Results Total effective rate of study group was significantly higher than that of control group (P < 0.05). The eradication rate of Hp in study group was significantly higher than that in control group (P < 0.05). The scores of stomachache fullness, belching and acid regurgitation, stomachache, stomachache and xerostomia in two groups after 90 days of treatment were lower than those before treatment, and the scores in study group were lower than those in control group (P < 0.05). The levels of serum hs-CRP, IL-6 and TNF-α in two groups after 90 days treatment were lower than those before treatment, and the level in study group was lower than that in control group (P < 0.05). There was no significant difference in incidence of adverse reaction between two groups (P > 0.05). Conclusion Jinghua Weikang Capsules combined with quadruple therapy in the treatment of Hp positive elderly patients with chronic gastritis can rapidly improve clinical symptoms, reduce the level of inflammatory factors, and the medication is safe and effective, which has a certain clinical application value.
|
|
|
|
|
|
[1] Bacha D，Walha M，Ben Slama S，et al. Chronic gastritis classifications [J]. Tunis Med，2018，96（7）：405-410.
[2] Sipponen P，Maaroos HI. Chronic gastritis [J]. Scand J Gastroenterol，2015，50（6）：657-667.
[3] 黄勇，张晓青，金忠芹，等.慢性胃炎组织病理特征和Hp感染与炎症程度的关系研究[J].现代生物医学进展，2017， 17（14）：2707-2710.
[4] 中华医学会老年医学分会，中华老年医学杂志编辑委员会.老年人慢性胃炎中国专家共识[J].中华老年医学杂志，2018，37（5）：485-491.
[5] 姜梅芳.荆花胃康胶丸联合三联疗法治疗老年幽门螺杆菌感染慢性胃炎的疗效[J].中国老年学杂志，2014，34（10）：2719-2720.
[6] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：126-127.
[7] 房静远，刘文忠，李兆申，等.中国慢性胃炎共识意见[J].胃肠病学，2013，18（1）：24-36.
[8] 周建中，陈泽民，危北海.慢性胃炎中西医结合诊断、辨证和疗效标准（试行方案）[J].中国中西医结合杂志，1990， 10（5）：318-319.
[9] 龙波.慢性胃炎症状与治疗[J].中西医结合心血管病电子杂志，2018，6（16）：36-37.
[10] 邢建伟，史凤磊，苏秋菊.通络解毒化浊汤对慢性萎缩性胃炎血液流变学及胃液成分的影响[J].国际中医中药杂志，2019，41（8）：805-808.
[11] Bie M，Wen J，Wang H，et al. Phylogenetic analysis of clinical strains of Helicobacter pylori isolated from patients with gastric diseases in Tibet [J]. Ann Transl Med，2019，7（14）：320.
[12] 吴素江，许小康，黄健，等.幽门螺杆菌感染与胃癌发生发展相关性研究[J].中华医院感染学杂志，2016，26（6）：1264-1266.
[13] 朱振坤，汪金云，罗守军.胃肠病患者幽门螺杆菌感染状况及耐药性分析[J].现代实用医学，2015，27（3）：332-333，349.
[14] 刘丹，陈慧娲，兰汉超.慢性胃炎中医治疗的研究进展[J].内蒙古中医药，2017，36（11）：101-102.
[15] 胡伏莲，成虹，张学智，等.多中心临床观察荆花胃康联合三联疗法治疗幽门螺杆菌相关性十二指肠溃疡和胃炎疗效及耐药分析[J].中华医学杂志，2012，92（10）：679-684.
[16] 张月苗，王婷婷，叶晖，等.荆花胃康胶丸联合三联疗法治疗幽门螺杆菌感染慢性胃炎疗效观察[J].中国中西医结合消化杂志，2013，21（11）：587-590.
[17] 黄星涛，张学智，李宁，等.荆花胃康胶丸对幽门螺杆菌耐药菌株体外抑菌作用的研究[J].中国中西医结合消化杂志，2010，18（5）：290-293.
[18] 祁旦巳，张旭彤，高宝辉，等.幽门螺杆菌感染与慢性胃炎患者胃黏膜病理变化的相关性分析[J].中华医院感染学杂志，2016，26（16）：3640-3642.
[19] 栾冰，曹禹卿，姜美玲.不同三联疗法对幽门螺杆菌根除价值的对比[J].中国医药科学，2019，9（21）：230-232， 242.
[20] 石巍.序贯疗法联合双歧杆菌三联活菌胶囊治疗幽门螺杆菌阳性消化性溃疡的临床观察[J].中国医药科学，2019，9（23）：257-259，273.
[21] 刘玲玲，营大礼，张会珍.荆花胃康胶丸联合四联疗法在幽门螺杆菌感染患者中的应用效果[J].中国现代医学杂志，2018，28（22）：117-121.
[22] 赵纯梅，刘庆东，郝亚宁，等.荆花胃康胶丸联合三联疗法治疗老年幽门螺杆菌感染慢性胃炎的疗效观察[J].贵州医药，2019，43（9）：1445-1447. |
|
|
|
